journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/30430928/ecological-impact-of-isolated-cognitive-relapses-in-ms
#1
Riccardo Meli, Luca Roccatagliata, Elisabetta Capello, Nicolò Bruschi, Antonio Uccelli, Gianluigi Mancardi, Matilde Inglese, Matteo Pardini
Isolated cognitive relapses (ICRs) are transient deficits in cognitive performance that are the only presentation of a multiple sclerosis (MS) relapse. Here, we evaluated the impact of ICRs on cognitive difficulties in daily activities (assessed with the Multiple Sclerosis Neuropsychological Screening Questionnaire, Informant Version (MSNQ-I)) to characterize ICRs' clinical relevance. We used 2-year-long retrospective data to compare 15 relapsing-remitting MS (RRMS) patients with ICRs with 57 RRMS patients presenting an asymptomatic gadolinium enhancing lesion (and no-ICRs)...
November 15, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30427266/warts-and-all-fingolimod-and-unusual-hpv-associated-lesions
#2
James Triplett, Allan G Kermode, Alastair Corbett, Stephen W Reddel
BACKGROUND: Fingolimod is used to reduce relapse rates in relapsing-remitting multiple sclerosis (MS). It is a sphingosine 1-phosphate (S1P) analogue having antagonistic effects on S1P receptors. Its immunosuppressive effect is due to reduced circulating lymphocyte numbers, and it may also be associated with impaired intrinsic cancer surveillance. Fingolimod side effects include increased rates and severity of viral infections particularly varicella zoster. METHODS: We present five cases of chronic and treatment refractory warts associated with fingolimod therapy...
November 14, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30427261/clinical-commentary-on-warts-and-all-fingolimod-and-unusual-hpv-associated-lesions
#3
Gabrielle Macaron, Daniel Ontaneda
No abstract text is available yet for this article.
November 14, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30421650/enhancing-natural-killer-cells-is-beneficial-in-multiple-sclerosis-commentary
#4
Benjamin M Segal
No abstract text is available yet for this article.
November 13, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30421642/enhancing-natural-killer-cells-is-beneficial-in-multiple-sclerosis-no
#5
Qiang Liu, Fu-Dong Shi
No abstract text is available yet for this article.
November 13, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30421641/enhancing-natural-killer-cells-is-beneficial-in-multiple-sclerosis-yes
#6
Alice Laroni
No abstract text is available yet for this article.
November 13, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30417718/cognitive-motor-interference-in-persons-with-multiple-sclerosis-during-five-upper-limb-motor-tasks-with-different-complexity
#7
Joke Raats, Ilse Lamers, Ilse Baert, Barbara Willekens, Renee Veldkamp, Peter Feys
BACKGROUND: Cognitive-motor interference in multiple sclerosis has been well examined during walking, but not during upper limb (UL) performance. OBJECTIVES: To examine the dual-task cost (DTC) in persons with multiple sclerosis (pwMS) and healthy controls (HC) in various type and complexity of UL motor tasks. METHOD: In total, 30 pwMS without major UL impairment and 30 HC performed five different UL tasks, in single condition and combined with the phonemic word list generation task...
November 12, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30417715/persistent-mog-igg-positivity-is-a-predictor-of-recurrence-in-mog-igg-associated-optic-neuritis-encephalitis-and-myelitis
#8
Luana Michelli Oliveira, Samira Luisa Apóstolos-Pereira, Milena Sales Pitombeira, Pedro Henrique Bruel Torretta, Dagoberto Callegaro, Douglas Kazutoshi Sato
BACKGROUND: MOG-IgG-associated optic neuritis, encephalitis and myelitis (MONEM) is a recently recognized group of inflammatory central nervous system (CNS) disorders distinct from multiple sclerosis and neuromyelitis optica spectrum disorders. Limited data are available regarding the predictors of relapse in this condition. OBJECTIVE: We aimed to evaluate the longitudinal serostatus of patients with MOG-IgG and to correlate serostatus with long-term clinical outcomes...
November 12, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30415593/ocrelizumab-reduces-progression-of-upper-extremity-impairment-in-patients-with-primary-progressive-multiple-sclerosis-findings-from-the-phase-iii-randomized-oratorio-trial
#9
Edward J Fox, Clyde Markowitz, Angela Applebee, Xavier Montalban, Jerry S Wolinsky, Shibeshih Belachew, Damian Fiore, Jinglan Pei, Bruno Musch, Gavin Giovannoni
BACKGROUND: Upper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS). OBJECTIVE: This exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and confirmed improvement (CI) in UE impairment in patients from ORATORIO. METHODS: Patients with PPMS received ocrelizumab 600 mg or placebo every 24 weeks for ⩾120 weeks. The Nine-Hole Peg Test (9HPT) was administered at baseline (BL) and every 12 weeks thereafter...
November 12, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30411658/development-of-the-arm-function-in-multiple-sclerosis-questionnaire-short-form-amsq-sf-a-static-10-item-version
#10
Michiel Aj Luijten, Iris Eekhout, Marie D'Hooghe, Bernard Mj Uitdehaag, Lidwine B Mokkink
BACKGROUND: Assessing arm and hand function of multiple sclerosis (MS) patients is important as impaired functioning may impact daily activities and reduce quality of life. OBJECTIVE: A short-form of the Arm Function in Multiple Sclerosis Questionnaire (AMSQ), a recently developed patient-reported outcome measure containing 31 items, is developed to allow non-adaptive application. METHODS: Complete data from 690 patients with MS, recruited via outpatient clinics, a residential center or via a Dutch website aimed at MS patients, were included in the analyses...
November 9, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30411655/patient-reported-outcome-measures-of-upper-limb-function-in-multiple-sclerosis-a-critical-overview
#11
Ilse Lamers, Peter Feys
No abstract text is available yet for this article.
November 9, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30403365/severe-b-cell-mediated-disease-activation-despite-two-cycles-of-alemtuzumab-in-a-patient-with-multiple-sclerosis
#12
Jae-Won Hyun, Yeseul Kim, Gayoung Kim, Su-Hyun Kim, Ho Jin Kim
Alemtuzumab is a potent monoclonal CD52 antibody used to treat patients with multiple sclerosis (MS). However, recent literature reports have described paradoxical activation of B cell-mediated disease within 1 year of the first cycle of alemtuzumab. We raise awareness that severe B cell-mediated disease activation could develop, even after two cycles of alemtuzumab, in some vulnerable MS patients; therefore, individualized therapeutic strategies should be considered in clinical practice. We also propose that a novel regulatory B-cell subset may be a candidate for a predictive biomarker of disease activation in MS patients treated with alemtuzumab...
November 7, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30381992/residual-disability-after-severe-relapse-in-people-with-multiple-sclerosis-treated-with-disease-modifying-therapy
#13
Anat Achiron, Ida Sarova-Pinhas, David Magalashvili, Yael Stern, Aviva Gal, Mark Dolev, Shay Menascu, Gil Harari, Michael Gurevich
BACKGROUND: The rate of post-relapse residual disability in patients with relapsing-remitting multiple sclerosis (RRMS) treated with disease-modifying drugs (DMD) has not been studied. OBJECTIVE: To assess relapse residual disability in DMD-treated RRMS patients. METHODS: We followed DMD-treated RRMS patients presenting with acute relapse who received high-dose steroids. Increases in Expanded Disability Status Scale (EDSS) of at least 2.0, 1...
November 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30381987/international-consensus-on-quality-standards-for-brain-health-focused-care-in-multiple-sclerosis
#14
Jeremy Hobart, Amy Bowen, George Pepper, Harriet Crofts, Lucy Eberhard, Thomas Berger, Alexey Boyko, Cavit Boz, Helmut Butzkueven, Elisabeth Gulowsen Celius, Jelena Drulovic, José Flores, Dana Horáková, Christine Lebrun-Frénay, Ruth Ann Marrie, James Overell, Fredrik Piehl, Peter Vestergaard Rasmussen, Maria José Sá, Carmen-Adella Sîrbu, Eli Skromne, Øivind Torkildsen, Vincent van Pesch, Timothy Vollmer, Magd Zakaria, Tjalf Ziemssen, Gavin Giovannoni
BACKGROUND: Time matters in multiple sclerosis (MS). Irreversible neural damage and cell loss occur from disease onset. The MS community has endorsed a management strategy of prompt diagnosis, timely intervention and regular proactive monitoring of treatment effectiveness and disease activity to improve outcomes in people with MS. OBJECTIVES: We sought to develop internationally applicable quality standards for timely, brain health-focused MS care. METHODS: A panel of MS specialist neurologists participated in an iterative, online, modified Delphi process to define 'core', 'achievable' and 'aspirational' time frames reflecting minimum, good and high care standards, respectively...
November 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30381985/assessment-of-computer-adaptive-testing-version-of-the-neuro-qol-for-people-with-multiple-sclerosis
#15
Brian C Healy, Jonathan Zurawski, Cindy T Gonzalez, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz
BACKGROUND: To date, the computerized adaptive testing (CAT) version of the Neuro-quality of life (QOL) has not been assessed in a large sample of people with multiple sclerosis (MS). OBJECTIVE: The aim of this study was to assess the associations between the CAT version of Neuro-QOL and other clinical and patient-reported outcome measures. METHODS: Subjects ( n = 364) enrolled in SysteMS completed the CAT version of the Neuro-QOL and the 36-Item Short Form Survey (SF-36) within 4 weeks of a clinical exam that included the Multiple Sclerosis Functional Composite-4 (MSFC-4)...
November 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30381984/multidisciplinary-data-infrastructures-in-multiple-sclerosis-why-they-are-needed-and-can-be-done
#16
Liesbet M Peeters, Caspar Ep van Munster, Bart Van Wijmeersch, Robin Bruyndonckx, Ilse Lamers, Niels Hellings, Veronica Popescu, Christoph Thalheim, Peter Feys
Personalized treatment is highly desirable in multiple sclerosis (MS). We believe that multidisciplinary measurements including clinical, functional and patient-reported outcome measures in combination with extensive patient profiling can enhance personalized treatment and rehabilitation strategies. We elaborate on four reasons behind this statement: (1) MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description, (2) functioning, progression, treatment, and rehabilitation effects are interdependent and should be investigated together, (3) personalized healthcare is based on the dynamics of system biology and on technology that confirms a patient's fundamental biology and (4) inclusion of patient-reported outcome measures can facilitate patient-relevant healthcare...
November 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30379124/unusual-presentations-of-mog-antibody-associated-central-nervous-system-demyelination-expanding-the-spectrum
#17
Romain Marignier
No abstract text is available yet for this article.
October 31, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30379117/paediatric-mog-antibody-associated-adem-with-complex-movement-disorder-a-case-report
#18
Mario Sa, Rachel Thornton, Wk Kling Chong, Marios Kaliakatsos, Yael Hacohen
Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are a well-recognized cause of acquired demyelinating syndromes in both adult and children. Despite basal ganglia involvement on imaging, movement disorder is not a cardinal feature. We describe a 2-year-9-month-old girl who presented with severe encephalopathy with aphasia, seizures and a complex movement disorder with dystonic posturing and tonic eye deviation. Neuroimaging revealed subtle asymmetrical predominantly white matter signal changes. MOG-Abs were positive in the serum...
October 31, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30379114/ocular-flutter-as-presenting-manifestation-of-pediatric-mog-antibody-associated-demyelination-a-case-report
#19
Marianthi Breza, Nikoletta Smyrni, Georgios Koutsis, Evangelos Anagnostou, John Tzartos, Georgios Velonakis, Constantinos Kokkinis, Constantinos Kilindireas, Antigone Papavasiliou, Charalambos Kotsalis
A 13-year-old girl presented with a 5-day history of oscillopsia. On examination, ocular flutter and mild cerebellar signs were found. Brain magnetic resonance imaging (MRI) revealed four periventricular and subcortical non-enhancing lesions. Cerebrospinal fluid (CSF) oligoclonal bands were negative. Neuroblastoma or other malignancies were not found. She responded well to a corticosteroid-intravenous immunoglobulin (IVIG) combination and remained symptom-free for 3 years until presenting again with isolated ocular flutter...
October 31, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30375937/clinical-commentary-on-de-novo-convulsive-status-epilepticus-in-patients-with-multiple-sclerosis-treated-with-dalfampridine
#20
Rachel Farrell
No abstract text is available yet for this article.
October 30, 2018: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"